About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Conference & CLE Calendar | Main | Generic Pharmaceutical Association Releases Report on Value of Pay-for-Delay Agreements »

October 02, 2011

Court Report

By Sherri Oslick --

Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Precision BioSciences, Inc. v. Cellectis SA et al.
5:11-cv-00513; filed September 26, 2011 in the Eastern District of North Carolina

• Plaintiff:  Precision BioSciences, Inc.
• Defendants:  Cellectis SA; Cellectis Bioresearch; Cellectis Bioresearch, Inc.

Infringement of U.S. Patent No. 8,021,867 ("Rationally Designed Meganucleases with Altered Sequence Specificity and DNA-Binding Affinity," issued September 20, 2011") based on Cellectis' manufacture and sale of certain products, including meganucleases targeting the human RAG1 gene, meganucleases targeting the HIV1 genome, and meganucleases targeting the GS gene in Chinese Hamster Ovary cells.  View the complaint here.


Helsinn Healthcare S.A. et al. v. Dr. Reddy's Laboratories, Ltd. et al.
3:11-cv-05579; filed September 23, 2011 in the District Court of New Jersey

• Plaintiffs:  Helsinn Healthcare S.A.; Roche Palo Alto LLC
• Defendants:  Dr. Reddy's Laboratories, Ltd.; Dr. Reddy's Laboratories, Inc.; Sandoz Inc.; Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries, Ltd.

Infringement of U.S. Patent No. 7,960,424 ("Liquid Pharmaceutical Formulations of Palonosetron," issued June 14, 2011 following a Paragraph IV certification as part of defendants filing of an ANDA to manufacture a generic version of Helsinn's Aloxi® (palonosetron hydrochloride intravenous solution, used to prevent chemotherapy induced nausea and vomiting).  View the complaint here.

Posted at 11:46 PM in Court Report |

Comments

The comments to this entry are closed.

November 2023

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30    

Categories

Archives

More...